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Abstract
We report the first safety and immunogenicity trial of the Plasmodium falciparum vaccine candidate FMP2.1/AS02A, a recombinant E.
coli-expressed protein based upon the apical membrane antigen-1 (AMA-1) of the 3D7 clone formulated with the AS02A adjuvant. We
conducted an open-label, staggered-start, dose-escalating Phase I trial in 23 malaria-naı̈ve volunteers who received 8, 20 or 40 g of FMP2.1
in a fixed volume of 0.5 mL of AS02A on a 0, 1, and 2 month schedule. Nineteen of 23 volunteers received all three scheduled immunizations.
The most frequent solicited local and systemic adverse events associated with immunization were injection site pain (68%) and headache
(29%). There were no significant laboratory abnormalities or vaccine-related serious adverse events. All volunteers seroconverted after
second immunization as determined by ELISA. Immune sera recognized sporozoites and merozoites by immunofluorescence assay (IFA),
and exhibited both growth inhibition and processing inhibition activity against homologous (3D7) asexual stage parasites. Post-immunization,
peripheral blood mononuculear cells exhibited FMP2.1-specific lymphoproliferation and IFN- and IL-5 ELISPOT assay responses. This
is the first PfAMA-1-based vaccine shown to elicit both potent humoral and cellular immunity in humans. Encouraged by the potential of
FMP1/AS02A to target host immunity against PfAMA-1 that is known to be expressed by sporozoite, hepatic and erythrocytic stages, we
have initiated field trials of FMP2.1/AS02A in an endemic population in the Republic of Mali.
© 2007 Elsevier Ltd. All rights reserved.
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1. Introduction
Malaria kills three children every minute, and afflicts
hundreds of millions of people each year [1]. The spread
of drug-resistant parasites, the lack of affordable effective
antimalarial drugs, and the inadequate use of insecticide-
impregnated bednets and household pesticides makes urgent
the quest to develop and deploy an effective malaria vaccine
[2].
The Plasmodium falciparum protein known as “apical
membrane antigen-1 (PfAMA-1)” is expressed in the sporo-
zoite [3], hepatic [4,5] and erythrocytic stages [6], and this
provides the rationale for a vaccine strategy that targets host
humoral and cellular immune responses against this protein
therefore targeting these three phases of parasite develop-
ment.
PfAMA-1 is a promising candidate vaccine antigen that
has not yet been evaluated for protective efficacy in clinical
trials. Evidence exists that such a strategy is worthwhile. Nat-
ural exposure to P. falciparum infection is associated with
both B-cell and T-cell responses to recombinant PfAMA-1
and to PfAMA-1 peptides [7–9]. Naturally acquired anti-
body to PfAMA-1 in endemic populations is associated with
protection from falciparum malaria [10,11]. Immunization of
New World monkeys with recombinant PfAMA-1 formulated
with Freund’s adjuvant has conferred significant protection
against homologous P. falciparum challenge [12,13], but lim-
ited protection when formulated with adjuvants intended for
human use such as Montanide or AS02A [Barnwell, unpub-
lished]. Several PfAMA-1 vaccines are in development, but
none have been tested for clinical efficacy [14–20]. A recent
Phase I clinical trial of a recombinant PfAMA-1 antigen
adjuvanted with alhydrogel showed that this formulation
elicited functional antibodies that, after affinity purifica-
tion, exhibited growth inhibition of P. falciparum in vitro
[21].
At the Walter Reed Army Institute of Research (WRAIR)
Pilot Bioproduction Facility, we produced a recombinant
protein, designated FMP2.1 [22], representing a major por-
tion of the ecto-domain of PfAMA-1 from the 3D7 clone
of P. falciparum. FMP2.1 was formulated in the Glaxo-
SmithKline proprietary adjuvant system, AS02A, which had
been shown to enhance the immunogenicity and efficacy of
the circumsporozoite-based malaria antigen, RTS,S [23–28].
RTS,S formulated with AS02A (RTS,S/AS02A) has pro-
tected approximately 41% of malaria-naı̈ve humans against
challenge with P. falciparum sporozoites [25]. RTS,S/AS02A
efficacy in a field trial was 35% (95% CI 22–47; p < 0.0001)
for protection against first clinical episodes and 49% (95%
CI 12–71; p = 0.02) for protection against severe malaria
during an 18 month period in young African children
[27,28].
Immunization of rabbits with a pre-clinical lot of FMP2.1
formulated with AS02A-induced functional antibodies with
strong growth inhibitory and processing inhibition activ-
ity in in vitro assays [29,30]. Evaluation of clinical grade
(cGMP, current Good Manufacturing Practice) FMP2.1 for-
mulated with AS02A in a standard rhesus monkey model
demonstrated that the vaccine was safe, minimally reac-
togenic, and able to induce potent cellular and humoral
immune responses, including growth inhibitory antibodies
against homologous P. falciparum 3D7 parasites (Stewart,
unpublished).
One strategy to augment the partial protective efficacy
of the RTS,S/AS02A vaccine is to combine it with one or
more antigens independently proven to limit or prevent para-
sitemia such as FMP2.1 [31]. Accordingly, we conducted the
present Phase 1 dose-escalation trial at the WRAIR Clinical
Trials Center in malaria-naı̈ve adults to establish a prelimi-
nary safety and immunogenicity profile before proceeding to
clinical trials of FMP2.1/AS02A in endemic populations in
the Republic of Mali.
2. Materials and methods
2.1. Vaccine
FMP2.1 antigen (Lot 0971), representing amino acids
#83-531 of the P. falciparum (clone 3D7) AMA-1 protein,
was manufactured according to current good manufactur-
ing practices (cGMP) at the Walter Reed Army Institute
of Research Bioproduction Facility at Forest Glen, Mary-
land [22]. The final FMP2.1 product was a single dose vial
containing approximately 43 g of lyophilized protein. Just
prior to immunization, the lyophilized protein was mixed
with AS02A such that approximately 8, 20 or 40 g of
FMP2.1 was delivered in a final volume of 0.5 mL of AS02A.
The adjuvant AS02A (Lot AS02A012A9), manufactured
by GlaxoSmithKline Biologicals (Rixensart, Belgium), con-
sists of an oil-in-water emulsion, and the immunostimulants
3-deacylated monophosphoryl lipid A (MPL) (GSK Biolog-
icals, Rixensart, Belgium) and QS21 derived from Quillaja
saponaria (Antigenics Inc., Lexington, MA, USA).
2.2. Ethics and monitoring
This clinical study was conducted under a protocol
reviewed and approved by the Human Use Review Com-
mittee of the Walter Reed Army Institute of Research and
by the Human Subjects Research and Review Board of the
Surgeon General of the U.S. Army at Fort Detrick, Mary-
land. The study protocol was submitted to the U.S. Food
and Drug Administration for review as part of Investigational
New Drug application BB-IND #11140. The study was moni-
tored for regulatory compliance and data quality assurance by
the United States Army Medical Material and Development
Activity, Fort Detrick, Maryland and by GlaxoSmithKline
Biologicals, Rixensart, Belgium. After obtaining written
informed consent, volunteers were screened by history, phys-
ical examination and laboratory testing to determine their
eligibility for enrollment.
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2.3. Protocol
The study was an open-label, staggered-start, dose-
escalating Phase 1 trial intended to determine the safety,
reactogenicity and immunogenicity of three intramuscularly
administered doses of FMP2.1/AS02A in healthy malaria-
naı̈ve adults at the WRAIR Clinical Trials Center.
Volunteers were sequentially assigned to one of three
dosage groups (Groups A, B, and C). Group A received
approximately 8 g FMP2.1 in 0.5 mL AS02A; Group B,
approximately 20 g FMP2.1 in 0.5 mL AS02A; and Group
C, approximately 40 g FMP2.1 in 0.5 mL AS02A.
2.3.1. Participants
Participants were adult males and females 18–45 years of
age. Exclusion criteria included history of malaria, previous
receipt of a malaria vaccine, splenectomy, known or sus-
pected immunosuppression, use of systemic steroids, recent
receipt of any investigational or non-registered drug or vac-
cine, simultaneous participation in any other clinical trial,
receipt of immunoglobulin or any blood product transfusion
within 3 months of study start, abnormal screening labo-
ratories (CBC, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), creatinine (Cr), or positive serum
beta-human chorionic gonadotrophin), serologic evidence of
active hepatitis B or C infection, antibody to HIV, or any
other clinically significant acute or chronic disease that might
confound the interpretation of study results.
2.3.2. Immunization procedures
Vaccine was administered by injection into the deltoid
of the non-dominant arm on a 0, 1, and 2 month immu-
nization schedule beginning with Group A. There was a
minimum 14-day interval between group immunizations to
allow for safety evaluation of the previous group. Follow-
up evaluations occurred on days 1, 2, 3, 7, and 14 after
each immunization and at 2, 4, and 6 months after the third
immunization.
2.3.3. Adverse events
The volunteers were observed for 30 min after each
immunization for evidence of anaphylaxis. The presence of
solicited local and general signs and symptoms, including
measurement of oral temperature, were assessed after each
immunization and 1, 2, 3 and 7 days post-immunization.
The solicited injection site adverse events were pain, red-
ness and swelling. Solicited general adverse events were
fever, gastrointestinal complaints, fatigue, headache, malaise,
myalgia and joint pain. In addition to the solicited signs
and symptoms, investigators recorded any other adverse
events occurring within a 28-day follow-up period (day
of immunization and 27 subsequent days) as unsolicited
adverse events. Adverse events were assessed for intensity.
Injection site pain was graded as 0 = absent, 1 = painful on
touch, 2 = painful when limb is moved, and 3 = spontaneously
painful. Solicited symptoms were graded as 0 = normal,
1 = easily tolerated, 2 = interferes with normal activity,
and 3 = prevents normal daily activity. Additional grad-
ing scales were applied to visible swelling or redness at
the injection site; 0 = none, 1 = 0–20 mm, 2 = 20–50 mm,
and 3 = >50 mm, and to oral temperature; 0 = <37.5 ◦C,
1 = 37.5–38 ◦C, 2 = 38–39 ◦C, and 3 = >39 ◦C.
Serious adverse events (SAEs) were reported from
enrollment until study completion 6 months after final
immunization. SAEs were defined as any untoward medical
occurrence that resulted in death, significant disability, hos-
pitalization, incapacity, or required intervention to prevent
such outcomes.
Biochemical (ALT, AST, and Cr) and hematological (Hb,
hct, WBC, and PLTs) laboratory parameters were measured
at screening, and on days of immunization, 2 weeks after




IgG antibody to the test antigen was measured by enzyme-
linked immunosorbent assay (ELISA) in all volunteers at
baseline, 2 weeks after each immunization and 2, 4, and
6 months after the third immunization. IgG ELISAs were
performed, using FMP2.1 as the capture antigen, in serial
two-fold dilution, and the titer defined as the serum dilution
required to yield an optical density of 1.0 in our assay.
2.4.2. Sporozoite and merozoite immunofluorescence
assay (IFA)
Blood stage late schizonts were fixed with methanol
and immunofluorescence assays (IFA) were performed as
described previously [22]. Briefly, 2% fetal bovine serum
containing PBS was used as a diluent and serial dilutions
starting from 1:2 to 1:25,600 were tested. FITC-conjugated
secondary antibodies diluted 1:500 (Southern Biotech, Birm-
ingham, AL, USA) were used and slides were mounted
in SlowFade® Antifade Kit with DAPI (4′,6′-diamidino-2-
phenylindole) (Molecular Probes, Inc. Eugene, OR, USA).
Sporozoite IFA utilized an acetone fixed preparation of sporo-
zoites and was performed with two pre-immunization and
post-third immunization serum samples from Group C. The
methodology was similar to the blood stage IFA except the
mounting solution did not contain DAPI. An Olympus BX50
microscope equipped with a mercury epifluorescence lamp,
a 100× (oil) objective and a multi filter cube was used to
observe the fluorescence.
2.4.3. Growth invasion/inhibition assay (GIA)
Sera were tested for growth inhibitory effects against
homologous 3D7 and heterologous FVO P. falciparum par-
asites in a one-cycle static assay [32]. Three time points for
each volunteer were evaluated: baseline, 2 weeks after sec-
ond immunization, and 2 weeks after third immunization. The
parasites were cultured for 2 days in heat inactivated, dialyzed
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sera (20%, v/v) at a 0.2% initial parasitemia (trophozoites)
and 4% hematocrit in triplicate 150 L static culture volumes
in 48-well plates. Cultures were harvested and stained with
Hoechst dye 33342 (Molecular Probes, Eugene, OR, USA)
and the number of new trophozoites were counted in 40,000
erythrocytes by flow cytometry. Inhibition was calculated
from final parasitemias as inhibition = (control-test)/control,
where control was the final parasitemia with pre-immune
serum, and was expressed as a percent.
2.4.4. Processing inhibition assay (PIA)
We have described an immuno-chemical correlate of
anti-AMA-1 antibodies that measures the ability of these
antibodies to inhibit the natural proteolytic processing of
PfAMA-1 on the merozoite surface [29,30]. We conducted
a parallel GIA and PIA on sera collected 2 weeks post
third immunization. The PIA was performed in a 48-well
plate format contained 80 L of purified late-stage schizonts
of the 3D7 strain of P. falciparum at a concentration of
1 × 107 mL−1 and 20 L test serum. The plate was gassed
with 5% CO2 and incubated at 37 ◦C until > 90% of schizonts
ruptured. The parasites were then collected by centrifugation
and analyzed by Western blot with biotin labeled polyclonal
anti-AMA-1 and biotin labeled monoclonal antibody against
the C-terminus of AMA-1, mAb 28G2dc1. This antibody
was a kind gift of Dr. Alan W. Thomas, Biomedical Pri-
mate Research Center, Rijswijk, The Netherlands. The PIA
ratio was calculated as band intensities of the 10-kDa/(10-
kDa + 20-kDa) AMA-1 specific bands on the Western blot
[29]. The GIA plate contained 80 L of 0.5% parasitemia
schizonts + normal human RBC at 4% hematocrit and 20 L
of test serum in triplicates. Plates were gassed and incu-
bated overnight at 37 ◦C; the percent invasion was determined
as described above, except the ring stages were stained by
SYBR® Green (Molecular Probes, Eugene, OR) dye for 1 h.
2.4.5. Cell-mediated immunity
For cellular reactivity of FMP2.1-immune cells we
measured lymphoproliferation as well as IFN- and IL-5
secretion. Briefly, cryopreserved and thawed peripheral blood
mononuclear cells (PBMC) obtained at pre- and post-third
immunization were re-suspended in RPMI plus additives and
5% human AB serum. For proliferation, cells were cultured at
a concentration of 2 × 105 cells/well in triplicates in 96-well
round bottom microtiter plates in the presence of FMP2.1 pro-
tein (10 g/mL), PHA (2 g/mL), or medium control. After 5
days cultures were pulsed with 3H-TdR (1 Ci/well) and har-
vested after an additional 16 h. Incorporation of radioactivity
was measured by scintillation spectrometry and results are
expressed as counts per minute (cpm). Stimulation indices
(SI) were determined according to the following formula:
SI = cpm in experimental culture
cpm in control cultures
.
IFN- and IL-5 responses were evaluated by the
ELISPOT assay. One hundred microlitres of cell suspensions
(2 × 106 mL−1 for IFN- and 4 × 106 mL−1 for IL-5) were
cultured in duplicates or triplicates in the presence of 0, 0.1,
1.0 or 10 g/mL FMP2.1 or 0.4 g/mL PHA in ELISPOT
wells coated previously with 100 L/well PBS contain-
ing 10 g/mL anti-IFN- or 15 g/mL anti-IL-5 (Mabtech,
Mairemont, OH, USA). After 18 h of culture in a 37 ◦C, 5%
CO2 humidified atmosphere, the plates were washed with
PBS, and 100 L of 1:100 dilution of appropriate biotiny-
lated detecting antibody (Mabtech) were added per well, and
plates were left for 2 h at room temperature. After washing,
100 L of a 1:1000 dilution of streptavidin–alkaline phos-
phatase conjugate (Mabtech) were added per well and the
plates were left for an additional 1.5 h at room temperature.
The plates were then washed and the ELISPOTs were devel-
oped by the addition of alkaline phosphatase substrate (Moss
Laboratories). The number of spots was counted with the
aid of an Immunospot Image Analyzer (Cellular Technology,
Cleveland, OH). Results are expressed as the mean ± S.E.M.
of triplicate wells for IFN- and duplicate wells for IL-5.
2.5. Statistics and data management
Data were entered into a Microsoft Excel spreadsheet data
base and analyzed using Excel statistical tools. In the case
of GIA analyses, data were compared using the Wilcoxon
signed-rank test (non-directional) with paired pre-immune
sera. Differences between groups were compared using the
Mann–Whitney-Wilcoxon rank-sum test (non-directional).
3. Results
3.1. Participant flow
The clinical portion of the study was conducted at the
Clinical Trials Center at the Walter Reed Army Institute of
Research from September 2003 to July 2004. Fifty-two vol-
unteers were screened. Twenty-three were eligible, enrolled
and allocated to one of the three dosage groups: Group A
(8 g FMP2.1 in 0.5 mL AS02A, n = 8), Group B (20 g
FMP2.1 in 0.5 mL AS02A, n = 8), and Group C (40 g
FMP2.1 in 0.5 mL AS02A, n = 7). Four volunteers did not
complete the immunization series. One volunteer from Group
A was withdrawn by the PI after first immunization due to
poor compliance with follow-up. One volunteer from Group
B was withdrawn by the PI after the first immunization
due to a severe adverse event not-related to immunization.
Two volunteers from Group C withdrew after the second
immunization; one withdrew without explanation, the other
withdrew due to Grade 3 adverse events associated with
immunization. Actual versus scheduled immunizations were
as follows: Group A; 22 of 24, Group B; 22 of 24, and Group
C; 19 of 21. During the 6 month post-immunization period, an
additional three volunteers did not complete follow-up; one
in Group A and two in group C. Thus, 16 of 23 volunteers
completed the study according to protocol (Fig. 1).
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Fig. 1. Volunteer flow diagram.
3.2. Safety and reactogenicity
Adverse events (AEs) by group are summarized in Table 1.
All solicited vaccine-related AEs occurred within 72 h after
vaccination. Sixteen Grade 3 reactions were reported with 12
of 16 occurring in the 40 g dosage group and the remain-
ing 4 occurred in the 20 g dosage group. Five of the Grade
3 reactions occurred in one individual in the 40 g group
after the second vaccination and were self-reported, as the
individual did not return for follow-up during the time he
was symptomatic. Local pain (43 incidents over 63 vacci-
nations), local swelling (10 incidents over 63 vaccinations),
myalgia (14 incidents over 63 vaccinations), and headache
(18 incidents over 63 vaccinations) accounted for most of
the solicited AEs. Almost all adverse events resolved within
the first 72 h after immunization. No clinically significant
biochemical or hematological abnormalities were associated
with immunization.
3.2.1. Serious adverse events (SAEs)
There was one SAE, and it was judged by the Principal
Investigator and the Medical Monitor to be not related to
Table 1
Instances of local and systemic solicited adverse events recorded during first 7 days after immunization summarized by group and by grade
Group A 8 g FMP2.1 in 0.5 mL AS02A Group B 20 g FMP2.1 in 0.5 mL AS02A Group C 40 g FMP2.1 in 0.5 mL AS02A
Grade1 Grade2 Grade3 Grade1 Grade2 Grade3 Grade1 Grade2 Grade3
Pain 6 4 0 6 13 1 6 7 0
Redness 0 0 0 0 0 1 4 0 2
Swelling 1 1 0 2 0 1 4 1 0
Fever 0 0 0 0 1 1 2 0 2
GI 0 0 0 3 1 0 3 2 0
HA 2 0 0 3 5 0 3 2 3
Malaise 0 0 0 1 2 0 1 1 2
Myalgia 2 1 0 3 2 0 3 2 1
Fatigue 0 0 0 2 2 0 2 4 1
Arthralgia 0 0 0 0 1 0 1 1 1
Total 11 6 0 20 27 4 29 20 12
Five Grade 3 events in Group C occurred in one volunteer after the second immunization. All solicited adverse events occurred within 72 h after immunization.
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Fig. 2. Anti-FMP2.1 titers by vaccine group. Each bar represents the group
average at a specific time expressed as a titer. Error bars depict one standard
deviation. Immunizations occurred on Days 0, 28 and 56 as indicated by
arrows.
immunization. Two days after first immunization, a female
volunteer from Group B (20 g dose group) presented with
palpitations, lightheadedness, and tachycardia by electrocar-
diogram. An extensive cardiology evaluation determined that
her symptoms and signs were consistent with a pre-existing
condition (paroxysmal supraventricular tachycardia) that was
deemed not causally related to immunization.
3.3. Serology
3.3.1. Anti-FMP2.1 antibody by ELISA
There was a robust three-log10 anti-PfAMA-1 antibody
(Ab) response after two immunizations in all three vaccine
groups as determined by ELISA (Fig. 2). After the second
immunization, the antibody response to all three dosages
was similar with no statistical differences between groups by
analysis of variance. Increases in antibody titer were most
pronounced after first and second immunization, with no
significant increase after third immunization. During the 6
months of follow-up after the third immunization, antibody
titers decayed by approximately one log10. All volunteers
in all three dosage groups seroconverted to FMP2.1 fol-
lowing the second immunization. The average coefficient
of variation of log titer at all subsequent time points after
the second injection was less than 10% for all vaccine
groups.
3.3.2. Antibody to P. falciparum merozoites
IFAs were conducted using sera collected after the third
immunization for 17 volunteers. Baseline IFA titers of the
pre-immune sera were 0–50. Fourteen of 16 volunteers devel-
oped a positive IFA titer ≥200. Median and range of IFA titers
for each group were as follows: Group A, 300 (0–25,600);
Group B, 4800 (800–12,800) and Group C, 1600 (800–6400).
Fig. 3A shows the typical pattern of AMA-1 distribution,
namely apical fluorescence of individual merozoites within
a schizont [22].
Fig. 3. Merozoite and sporozoite IFA results. (A) Blood stage schizont
immuno-stained with post third immunization sera at 1:800 dilution (primary
antibody). (B) Phase contrast and (C) fluorescence images of a sporozoite
immuno-stained with post third immunization sera at 1:100 dilution. (D)
Phase contrast and (E) fluorescence image of a sporozoite stained with
pre-immune sera at 1:100 dilution.
3.3.3. Antibody to P. falciparum sporozoites
Sera selected from two volunteers in Group C on the
basis of high post third immunization anti-FMP2.1 titers
reacted with sporozoites. Post third immunization sera, but
not pre-immunization sera, from both of these two indi-
viduals yielded a characteristic apical and circumferential
flourescence pattern [3]. Fig. 3B–E shows representative flu-
orescence patterns from one volunteer’s pre-immune sera
(Fig. 3D and E) and post-third immunization sera (Fig. 3B
and C).
3.3.4. Growth/invasion inhibition assay
Significant inhibition of merozoite invasion was induced
in the static in vitro assay against homologous P. falciparum
3D7 parasites. The mean inhibition of all the pre-immune
sera in Groups A, B and C was found to be 1% with a
range of 4 to −7% inhibition when compared to normal
control human serum, Combining all the volunteers in all
three groups led to significant (p < 0.001) average inhibition
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Fig. 4. Growth invasion/inhibition assay (GIA) by static culture method.
y-Axis denotes % inhibition in growth by 1:5 diluted immune sera in compar-
ison to matched pre-immune sera (which in turn were all within 6% of normal
media controls). Comparing growth with paired pre-immune sera using
the Wilcoxon signed-rank test (non-directional), *p < 0.05 or **p < 0.001.
Error bars are standard error of the mean. Av Group = the average of all
individuals within a group (6–7 volunteers) or all groups. 2wk p2 = sera col-
lected 2 weeks post second immunization; 2wk p3 = sera collected 2 weeks
post third immunization. There were no significant differences between any
groups (or between any 2wk p2 or 2wk p3 or pooled groups) using the
Mann–Whitney-Wilcoxon rank-sum test (non-directional, all p > 0.1).
after both second and third immunization (average inhibition
of 13 and 17%, respectively) compared to matched pre-
immunization controls (Fig. 4). Within groups, there was a
trend toward higher average inhibition after the third immu-
nization and higher average inhibition with increased antigen
(20 and 40 g dosage groups compared to the 8 g dosage
group) but this did not reach statistical significance using the
Mann–Whitney-Wilcoxon rank-sum test (non-directional, all
p > 0.1). When the same serum samples were tested against
FVO parasites, a heterologous strain of P. falciparum, no
inhibition of invasion was observed (data not shown). The
persistence of inhibitory antibody was not determined.
There was a positive correlation between the ELISA titers
and GIA activity of individual serum samples. The coefficient
of correlation squared (R2) was 0.38. When a single outlier
that gave 82% inhibition was eliminated, R2 increased to 0.75
(Fig. 5A).
3.3.5. Processing inhibition assay
We measured the PIA activity of 17 serum samples col-
lected 2 weeks post third immunization and 2 pre-immune
controls. The average PIA ratio for pre-immune controls
was 0.13. The average and range for vaccine groups were;
Group A 0.26 (0.19–0.36), Group B 0.22 (0.16–0.32), and
Group C 0.21 (0.14–0.43). There was no significant differ-
ence between the three vaccine groups. The PIA activity
positively correlated with GIA activity with an R2 of 0.585
Fig. 5. (A) Correlation of ELISA and GIA. The ELISA end-point
titers × 1000 (y-axis) were plotted against the corresponding percent inhibi-
tion in the static one-cycle GIA (x-axis) [30]. Data include 37 serum samples
collected 2 weeks post second and 2 weeks post third immunization of the
vaccine. (B) Correlation of GIA and PIA. The PIA ratio (x-axis) was plot-
ted against the corresponding percent inhibition in the static one-cycle GIA
(y-axis) [27]. Data include 17 serum samples collected 2 weeks post third
immunization and two pre-immunization controls.
(Fig. 5B). The R2 correlation between PIA versus ELISA and
GIA versus ELISA was 0.471 and 0.479, respectively (graphs
not shown).
3.3.6. Cell-mediated immunity
Significant lymphocyte proliferation was measured in
all three groups after third immunization with stimulation
indices ranging between 5 and 96 (data not shown). IFN-
production was detected in cultures stimulated with FMP2.1
at concentrations ranging from 0.1 to 10 g/mL; however, the
most robust response was elicited with 10 g/mL of FMP2.1
(Fig. 6) across all three groups. Means and ranges for IFN-
were similar, that is 578 (65–995), 765 (195–995) and 750
(615–905) spots per 106 PBMC for Groups A, B and C,
respectively. We also detected IL-5 in cultures of FMP 2.1-
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Fig. 6. IFN- response by ELISPOT. IFN- response by ELISPOT
at baseline (pre-immunization) or post third dose immunization (post-
immunization) by vaccine group in response to in vitro stimulation with
0.1, 1.0, or 10 g of FMP2.1. Error bars represent standard error of the
means (mean + S.E.M.).
Fig. 7. IL-5 response by ELISPOT. IL-5 response by ELISPOT at baseline
(pre-immunization) or post third dose immunization (post-immunization) by
vaccine group in response to in vitro stimulation with 0.1, 1.0, or 10 g of
FMP2.1. Error bars represent standard error of the means (mean + S.E.M.).
immune PBMC, and the responses were likewise FMP2.1
concentration-dependent with 10 g/mL eliciting maximum
cytokine production (Fig. 7). IL-5 responses were of lesser
magnitude than that seen for IFN-, with means and ranges
of 34 (14–50), 84 (11–154) and 47 (15–113) spots per 106
PBMC for Groups A, B and C, respectively.
4. Discussion
This is the first immunization of humans with
FMP2.1/AS02A. The vaccine was reactogenic but gener-
ally well-tolerated with no vaccine-related serious adverse
events. The vaccine proved to be highly immunogenic
inducing both humoral and cellular responses. In addi-
tion, the vaccine induced invasion and PfAMA-1 proteolytic
processing-inhibitory antibodies against homologous P. fal-
ciparum parasites.
4.1. Safety and reactogenicity
There were apparent differences among the dosage groups
in numbers of vaccine-associated adverse events in this small
study, with the higher dose groups having more solicited
adverse events. The duration of adverse events was similar
for all the groups with the majority resolving within 72 h
of immunization. However, because all the groups received
the same dose of adjuvant in their vaccine formulation, any
real differences in reactogenicity by dosage group would be
attributable to the amount of antigen. It should be noted how-
ever, that the pattern of the 16 Grade 3 adverse events has
been well documented in a small percentage of volunteers
who have received other AS02A vaccine formulations, so
the finding is not unique to the FMP2.1/AS02A formulation
[24,25]. There were no vaccine-related clinical laboratory
abnormalities.
4.2. Antibody responses
After the second immunization, there was no significant
difference in antibody response between dose groups. Fol-
lowing three immunizations, all three dosage groups had high
antibody levels by ELISA that persisted for 6 months after the
last immunization. Two immunizations appear to be enough
to induce a maximal antibody response, but since a third
immunization was given, its impact on antibody kinetics is
unclear.
The potential for FMP2.1-specific antibodies to inhibit
parasite invasion of erythrocytes in vivo was demonstrated
by the finding of functionally active antibody by both GIA
and PIA in all dose groups against homologous P. falci-
parum 3D7 parasites. It is important to note that the GIA
was done at 1:5 dilution, hence anti-FMP2.1 antibody levels
in vivo would be higher and presumably more active. The
trend toward greater inhibition in the GIA with higher doses
of antigen did not reach statistical significance, perhaps due
to small group sizes and variability in inhibition among indi-
viduals in each group. The percent growth invasion inhibition
assay (GIA) also positively correlated with the ELISA and
with the processing inhibitory assay (PIA) activity of anti-
FMP2.1, consistent with our hypothesis that antibodies are
an important component of PfAMA-1 immunity and that the
processing inhibition may be causally related to inhibition
of invasion [29,30]. Although GIA and PIA are not estab-
lished as a correlate of protection in humans, these functional
humoral response assays are likely to play an important role
in the evaluation of future trials of this and other PfAMA-
1 vaccines, as well as other vaccines exhibiting these or
similar activities. The relevance of the absence of activity
against heterologous P. falciparum FVO parasites in a GIA
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assay remains to be determined in field trials. The P. falci-
parum FVO and 3D7 PfAMA-1 ecto-domains differ at 24
amino-acid positions which represents the two most distant
haplotypes reported [33].
The demonstration that FMP2.1/AS02A-induced antibod-
ies recognized sporozoites by IFA further suggests a potential
role of this vaccine in inducing antibodies that might interfere
with the invasion of sporozoites into liver hepatocytes.
4.3. Cellular immunity
The cell-mediated immune (CMI) results indicate that
FMP2.1/AS02A produces a strong Th1 and a somewhat
weaker Th2 response. Given the expectation that antibody
may play a dominant role in controlling blood stage infec-
tion, these CMI responses suggest adequate T cell help
for the B cell response. Furthermore, the CMI response
may have implications beyond support of antibody response.
T lymphocytes from volunteers immunized with irradiated
P. falciparum sporozoites recognize PfAMA-1, and may
contribute to sterile immunity against virulent sporozoite
challenge by targeting falciparum-infected hepatocytes [4].
In AMA-1 vaccinated mice challenged with P. chabaudi, Xu
et al. demonstrated that AMA-1-specific T-cells played a role
in controlling parasitemia independent of antibody activity
[34]. Taken together, these observations suggest that T-cells
induced by FMP2.1/AS02A might act against PfAMA-1
expressed in pre-erythrocytic as well as on blood stages [4,5].
4.4. PfAMA-1 vaccine design
Blood stage malaria antigens, including PfAMA-1, exist
as diverse alleles that elicit varying degrees of cross-reactive
antibody. Sero-epidemiologic evidence [35], and the limited
GIA data presented here, suggest a PfAMA-1-based vac-
cine may elicit allele-specific antibodies. Consequently, in
addition to monovalent PfAMA-1 vaccines [14–17,21] there
are also bivalent PfAMA-1 vaccines in development in an
effort to broaden protective immune responses [18,19,21].
With FMP2.1/AS02A, we intend to determine if high titer
antibodies elicited against sporozoite and asexual stages, as
well as potent anti-PfAMA-1 cellular responses, might act
against diverse alleles. For this reason, initial field trials of
FMP2.1/AS02A will include allelic genotyping endpoints
to determine its ability to protect against parasites bearing
homologous and heterologous alleles of PfAMA-1 [36].
4.5. Conclusion
This pilot study has established the initial safety, reac-
togenicity and immunogenicity profile for FMP2.1/AS02A,
a PfAMA-1-based vaccine that elicited potent humoral and
Th1-biased cellular immune responses. Further studies are
already underway to evaluate this vaccine in volunteers liv-
ing in malaria-endemic regions. Thus, a Phase 1B trial in
children is now ongoing in Bandiagara, Mali, where subse-
quent trials are planned to determine its safety and efficacy
in children [37].
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